Shares of Merus Labs International Inc (TSE:MSL) have earned an average recommendation of “Buy” from the nine analysts that are covering the firm. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 1 year target price among analysts that have covered the stock in the last year is C$2.79.

A number of research firms recently issued reports on MSL. TD Securities reaffirmed a “buy” rating and set a C$4.00 price target on shares of Merus Labs International in a research note on Tuesday, August 16th. Scotiabank decreased their price target on shares of Merus Labs International from C$2.25 to C$1.75 and set a “sector perform” rating on the stock in a research note on Tuesday, August 16th. Paradigm Capital decreased their price target on shares of Merus Labs International from C$2.25 to C$1.75 and set a “hold” rating on the stock in a research note on Tuesday, August 16th. CIBC decreased their price target on shares of Merus Labs International from C$2.90 to C$2.50 in a research note on Tuesday, August 16th. Finally, Canaccord Genuity decreased their price target on shares of Merus Labs International from C$4.25 to C$3.50 and set a “buy” rating on the stock in a research note on Tuesday, August 16th.

Merus Labs International (TSE:MSL) traded up 1.54% during midday trading on Tuesday, reaching $1.32. 251,951 shares of the company traded hands. The company has a 50 day moving average price of $1.40 and a 200-day moving average price of $1.69. The stock’s market capitalization is $154.44 million. Merus Labs International has a one year low of $1.18 and a one year high of $2.40.

About Merus Labs International

Merus Labs International Inc (Merus) is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products in Canada and internationally. It carries out business principally in Canada and Europe. The Company has products in the area of urology/women’s health and anti-infectives.

Receive News & Ratings for Merus Labs International Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus Labs International Inc and related companies with MarketBeat.com's FREE daily email newsletter.